We present the case of a 28-year-old female patient with advanced myelodysplastic syndrome. Her BM examination at diagnosis showed the presence of 16% blasts and multi-lineage dysplasia, findings consistent with refractory anemia with excess blasts-2 (RAEB-2). Cytogenetic analysis revealed a deletion 5q and the rare translocation t(3;12)(q26;p13) with rearrangement of the ecotropic viral integration-1 gene (EVI1) by FISH. An allogeneic hematopoietic SCT (HSCT) was considered to be urgent due to the high-risk nature of her disease. Unfortunately, neither a family nor a matched unrelated donor was available. We therefore decided to proceed with a cord blood transplantation from a 6/6 HLA-matched donor. The unit contained a total nucleated cell dose of 3.87 Â 10 7 /kg; both donor and recipient were seronegative for CMV. The preparative regimen included fractioned TBI (12 Gy), CY (120 mg/kg) given over two days and fludarabine (75 mg/m 2 ) in three doses. GVHD prophylaxis consisted of tacrolimus (beginning on day À3) and mycophenolate mofetil (as of day þ 1).
The patient developed acute headache and systolic hypertension during graft infusion. She seized 2 h later and was subsequently transferred to the intensive care unit for further investigation and monitoring. Magnetic resonance imaging of the brain showed multiple white matter lesions, compatible with posterior reversible encephalopathy syndrome. GVHD prophylaxis with tacrolimus was stopped as this drug was suspected to contribute to the formation of the lesions. 1 Sirolimus was used as replacement (loading dose of 12 mg, followed by daily oral intake aiming at blood trough levels of 8-12 ng/L). On day þ 19, a chest CT scan performed for investigation of neutropenic fever showed a small pericardial effusion. In the subsequent days, the patient developed signs of rapidly progressive cardiac tamponade, necessitating pericardiocentesis, which was performed on day þ 28. A volume of 350 mL of strawcolored clear fluid was drained. Analysis of pericardial fluid was compatible with a transudate (pericardial fluid LDH/ serum LDH ratio o0.6). The differential cell count showed 70% mesothelial cells, 26% monocytes, 1% lymphocytes and 3% polymorphonuclear cells. Cytology was negative for malignant cells, as well as gram stain and cultures. On day þ 35, symptoms of tamponade recurred. A second urgent pericardiocentesis was repeated and 600 mL of fluid was drained. Once again, analysis of the cardiac effusion specimen was consistent with a transudate. Methylprednisolone was introduced at a dose of 50 mg/day because of the possibility of immune-mediated capillary leak syndrome. Sirolimus was discontinued simultaneously because of suspected contribution to the pericardial effusion. Because of persistent cytopenias and fever, peripheral blood PCR for human herpesvirus 6 (HHV-6) was performed and found to be positive at a level of 1.3 Â 10 4 copies/mL, whereas pericardial fluid PCR results for HHV-6 were found to be positive at 2.43 Â 10 5 copies/mL. Antiviral therapy with foscarnet (45 mg/kg i.v. every 8 h for 12 days) was introduced three days after discontinuation of sirolimus for treatment of HHV-6 infection. This was done in an effort to treat all possible causes of recurrent pericardial effusion in the face of clinical deterioration of the patient's condition. The patient improved dramatically; there was no further pericardial fluid re-accumulation as demonstrated by serial cardiac echographies.
The patient was eventually discharged and is currently followed as an outpatient. Prednisone was tapered over the subsequent weeks. As of day þ 180, no signs of acute GVHD were noted using prophylaxis with mycophenolate mofetil only.
Pericardial tamponade is a potentially life-threatening condition. Common causes include previous pericarditis, cardiac trauma or myocardial perforation related to catheter or pacemaker insertion. Pericarditis can be caused by myocardial infarction, infections, neoplastic diseases, renal failure, autoimmune diseases, drug reactions, postmediastinal radiation therapy or as an idiopathic phenomenon. 2 Clinically significant pericardial effusions in the immediate post transplant setting are rare (1-4%), mainly thought to be manifestations of GVHD. Some case reports have also reported an association with infections and drug toxicities. 3, 4 To our best knowledge, there are no reported associations between HHV-6 infection and occurrence of pericardial tamponade, whereas HHV-6 viremia has been reported with a frequency as high as 70-80% in recipients of cord blood transplants without any notable clinical consequences in most patients, 5, 6 making HHV-6 an unlikely contributive pathogen for this case of cardiac tamponade. In sharp contrast, several cases of sirolimusrelated pericardial effusions in the setting of solid-organ transplantation have been reported, occurring with a frequency ranging from 0.5-5%. 7, 8 In HSCT, GVHD prophylaxis consists mainly of administration of calcineurin inhibitors. Reported data on GVHD prophylaxis with sirolimus after cord blood transplantation are sparse. 9, 10 To date, the pathophysiology of sirolimusinduced pericardial effusion is not clearly understood. We hypothesize that sirolimus was the most likely cause of pericardial effusion in this case, although the role of HHV-6 cannot be excluded completely.
In conclusion, this case illustrates an unusual complication after allogeneic HSCT. To our knowledge, this is the first reported case of possible sirolimus-induced pericardial effusion after SCT. Transplant physicians should be aware of this potentially life-threatening complication when using sirolimus for prophylaxis or treatment of GVHD.
